PHS
ALKS icon

PFM Health Sciences’s Alkermes ALKS Stock Holding History

PFM Health Sciences’s Portfolio ALKS Stock Details ALKS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-80,719
Closed -$2.32M – 68
2024
Q4 		$2.32M Sell
80,719
-124,354
-61% -$3.58M 0.14% 69
2024
Q3 		$5.74M Hold
205,073
– – 0.33% 49
2024
Q2 		$4.94M Sell
205,073
-224,500
-52% -$5.51M 0.24% 60
2024
Q1 		$11.6M Buy
+429,573
New +$12.2M 0.55% 52
2023
Q4 		– Sell
-1,162,030
Closed -$32.5M – 65
2023
Q3 		$32.5M Buy
1,162,030
+10,646
+0.9% +$312K 1.53% 28
2023
Q2 		$36M Buy
+1,151,384
New +$34.9M 1.4% 32

Other funds holding ALKS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

PFM Health Sciences's ALKS Position: Q1 2025 in Review

PFM Health Sciences sold out of Alkermes (ALKS) in Q1 2025, closing a stake of 80,719 shares — an estimated $2.32M sold.

PFM Health Sciences first reported a position in ALKS in Q2 2023 and held it in 6 quarters. The position peaked at $36M in Q2 2023. 371 funds tracked by Wall St. Rank hold ALKS as of Q1 2025.

  • PFM Health Sciences reported no remaining Alkermes position as of Q1 2025 after selling out during the quarter.
  • PFM Health Sciences sold 80,719 Alkermes shares in Q1 2025, an estimated $2.32M.
  • PFM Health Sciences first reported a position in Alkermes in Q2 2023 and held it in 6 quarters.
  • PFM Health Sciences's Alkermes position peaked at $36M in Q2 2023.
  • 371 funds tracked by Wall St. Rank held Alkermes as of Q1 2025.

Based on PFM Health Sciences's 13F filing for Q1 2025, filed 15 May 2025.